Tekmira Secures $3M Loan, Discloses Trial Date for Alnylam Litigation | GenomeWeb

Tekmira Pharmaceuticals said this week that it has secured a $3 million loan, extending its cash runway into 2013.

Separately this week, Tekmira announced that a trial date of Oct. 30, 2012 has been set for its litigation with Alnylam Pharmaceuticals and AlCana Technologies.

According to the company, Silicon Valley Bank has agreed to provide a $3 million term loan, which can be drawn down at Tekmira's discretion at any time before Sept. 30, 2012. The loan matures on June 30, 2015, and carries a fixed annual interest rate of 8 percent.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: certain genes repressed during memory formation, analysis of genomes from single neurons, and more.

NASA plans to test whether DNA sequencing studies can be conducted in microgravity.

Congress passes a continuing resolution to keep the US federal government funded through mid-December.

The Human Genome Project was launched 25 years ago, and at Nature, Francis Collins, James Watson, and Eric Green look back at the lessons learned.